SUMMARY: This study aimed to evaluate the prevalence of vertebral fractures to investigate the determinants of vertebral fracture risk in patients with COPD. The risk of vertebral fractures is strictly related to the severity of the disease. The use of glucocorticoids and the presence of low values of quantitative ultrasound (QUS) may represent additional risk factors. INTRODUCTION: Chronic obstructive pulmonary disease (COPD) appears to be associated with osteoporosis. Our study aimed to evaluate the prevalence of vertebral fractures and to investigate the main determinants of vertebral fracture risk in patients with COPD. METHODS: In 3,030 ambulatory COPD patients (1,778 men and 1,262 women) aged 50 years or over, we evaluated: COPD severity, presence of vertebral fractures on lateral chest X-ray and bone status by using a quantitative ultrasound device. RESULTS: In men there was a strong association between COPD severity and fractures (p < 0.001), conversely in women the association between COPD severity and fractures was at limit (p = 0.049). In men, but not in women, glucocorticoid treatment was significantly associated with vertebral fractures. The patients with high or moderate risk of osteoporosis presented an increased risk of vertebral fracture (OR 2.71; 95% CI 2.04-3.60 and OR 1.54; 95% CI 1.26-1.88, respectively). Logistic regression analysis showed that COPD severity and glucocorticoid treatment, both inhaled and oral, were associated with increased risk of vertebral fractures. CONCLUSION: In COPD patients the risk of vertebral fractures is strictly related to the severity of the disease. The use of glucocorticoids and reduced QUS at calcaneous may represent additional risk factors.
SUMMARY: This study aimed to evaluate the prevalence of vertebral fractures to investigate the determinants of vertebral fracture risk in patients with COPD. The risk of vertebral fractures is strictly related to the severity of the disease. The use of glucocorticoids and the presence of low values of quantitative ultrasound (QUS) may represent additional risk factors. INTRODUCTION:Chronic obstructive pulmonary disease (COPD) appears to be associated with osteoporosis. Our study aimed to evaluate the prevalence of vertebral fractures and to investigate the main determinants of vertebral fracture risk in patients with COPD. METHODS: In 3,030 ambulatory COPDpatients (1,778 men and 1,262 women) aged 50 years or over, we evaluated: COPD severity, presence of vertebral fractures on lateral chest X-ray and bone status by using a quantitative ultrasound device. RESULTS: In men there was a strong association between COPD severity and fractures (p < 0.001), conversely in women the association between COPD severity and fractures was at limit (p = 0.049). In men, but not in women, glucocorticoid treatment was significantly associated with vertebral fractures. The patients with high or moderate risk of osteoporosis presented an increased risk of vertebral fracture (OR 2.71; 95% CI 2.04-3.60 and OR 1.54; 95% CI 1.26-1.88, respectively). Logistic regression analysis showed that COPD severity and glucocorticoid treatment, both inhaled and oral, were associated with increased risk of vertebral fractures. CONCLUSION: In COPDpatients the risk of vertebral fractures is strictly related to the severity of the disease. The use of glucocorticoids and reduced QUS at calcaneous may represent additional risk factors.
Authors: N Bonnet; C L Benhamou; B Brunet-Imbault; A Arlettaz; M N Horcajada; O Richard; L Vico; K Collomp; D Courteix Journal: Bone Date: 2005-09-12 Impact factor: 4.398
Authors: Giuseppe Guglielmi; Luca Pio Stoppino; Maria Grazia Placentino; Francesco D'Errico; Francesco Palmieri Journal: Eur J Radiol Date: 2007-12-19 Impact factor: 3.528
Authors: Frank de Vries; Sander Pouwels; Madelon Bracke; Hubert G M Leufkens; Cyrus Cooper; Jan-Willem J Lammers; Tjeerd-Pieter van Staa Journal: Pharmacoepidemiol Drug Saf Date: 2007-06 Impact factor: 2.890
Authors: K Bleicher; R G Cumming; V Naganathan; M J Seibel; P N Sambrook; F M Blyth; D G Le Couteur; D J Handelsman; H M Creasey; L M Waite Journal: Osteoporos Int Date: 2010-11-26 Impact factor: 4.507